US2009264634A1PendingUtilityA1

Sequences characteristic of hypoxia-regulated gene transcription

Assignee: QUARK PHARMACEUTICALS INCPriority: Aug 21, 1997Filed: Nov 12, 2008Published: Oct 22, 2009
Est. expiryAug 21, 2017(expired)· nominal 20-yr term from priority
C07K 14/4747A61K 38/00A61K 48/00C12Q 1/6883C12N 9/0004C12Q 2600/158C12Y 114/11004C07K 14/4702C07K 14/47
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There are provided polynucleotides that are modulated by hypoxic conditions. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are also disclosed. The presence of hypoxia or a hypoxia-associated pathology may be diagnosed by screening for the presence of at least one polynucleotide having the nucleic acid sequence according to the present invention. Methods of regulating hypoxia associated pathologies are also provided.

Claims

exact text as granted — not AI-modified
1 . A polynucleotide comprising the sequences of any one of SEQ ID NOs:1, 3, 5, 7, 9, 10, 12, 14, 16, 18, and 19. 
     
     
         2 . An isolated polynucleotide having the sequence of
 (a) any one of SEQ ID NOs: 1, 3, 5, 7, 9, 10, 12, 14, 16, 18, and 19;   (b) a naturally-occurring polynucleotide comprising a sequence of (a); or   (c) a naturally-occurring polynucleotide having at least 70% identity with a naturally-occurring polynucleotide of (b) and, in naturally-occurring neural cells, has its expression modulated when the cells are subjected to neurotoxic stress;   (d) a naturally-occurring polynucleotide capable of hybridizing under moderately stringent conditions to a naturally-occurring polynucleotide of (b) and, in naturally-occurring neural cells, has its expression modulated when the cells are subjected to neurotoxic stress;   (e) a fragment of a polynucleotide of (a), (b), (c) or (d) having at least 20 nucleotides; or   (f) a polynucleotide sequence complementary to a polynucleotide of (a), (b), (c), (d) or (e).   
     
     
         3 . An isolated polynucleotide in accordance with  claim 2 , wherein said sequence of (a) is SEQ ID NO:3. 
     
     
         4 . An isolated polynucleotide in accordance with  claim 2  comprising a strand of a full-length cDNA. 
     
     
         5 . An isolated polynucleotide in accordance with  claim 3  comprising a strand of a full-length cDNA. 
     
     
         6 . An isolated polynucleotide encoding the polypeptide of SEQ ID NO:4.

Join the waitlist — get patent alerts

Track US2009264634A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.